Our Response to COVID-19

At the time of this writing we are in the midst of global pandemic with over 3,000,000 confirmed coronavirus cases and over 220,000 deaths. As a company in the healthcare space, we felt obliged to respond.


Our team is developing and clinically validating Septane, a precision medicine that can impact the treatment of COVID-19. We are particularly focused on patients who have progressed to pulmonary fibrosis, interstitial lung disease, sepsis, or are on a breathing apparatus.


Advanced Innovative Partners (AIP) is committed to supporting the global community that is being affected by the coronavirus. We will keep you up to date as our research progresses.